Specifically, compared with treatment-naive and non-MPR patients, neoadjuvant MPR patients had more CD20+ B cell infiltration and a significantly higher proportion of B-cell subclasses IgG1 and IgG3 positive cells, and the ratio of IgA positive cells was significantly lower than that in treatment-naive and non-MPR tumor tissues. The gene discussed is IGHG3; the disease is neoplasm.